

USPTO PATENT FULL-TEXT AND IMAGE DATABASE**Home****Quick****Advanced****Pat Num****Help****Bottom****View Cart**

10/763, 023

Searching 1976 to present...

Results of Search in 1976 to present db for:**((AN/wisconsin AND 2-methyl) AND 2-alkyl): 13 patents.***Hits 1 through 13 out of 13***Jump To****Refine Search**

an/wisconsin and 2-methyl and 2-alkyl

PAT.
NO. Title

- 1 6,846,811 T (20S) 1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 2 6,844,457 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 3 6,844,332 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 4 6,844,331 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 5 6,844,330 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-NOR-vitamin D3 and their uses
- 6 6,806,262 T 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
- 7 6,667,298 T 26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds
- 8 6,627,622 T (20S)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
- 9 6,579,861 T 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
- 10 6,566,352 T 1 .alpha.-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
- 11 6,544,969 T 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds
- 12 6,440,953 T 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
- 13 6,316,642 T 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds

Top**View Cart****Home****Quick****Advanced****Pat Num****Help**

USPTO PATENT FULL-TEXT AND IMAGE DATABASE**Home****Quick****Advanced****Pat Num****Help****Bottom****View Cart***Searching 1976 to present...***Results of Search in 1976 to present db for:***10/763,023***((IN/deluca AND 2-methyl) AND 2-alkyl): 13 patents.***Hits 1 through 13 out of 13***Jump To****Refine Search**

in/deluca and 2-methyl and 2-alkyl

PAT. NO.	Title
-------------	-------

- 1 6,846,811 T (20S) 1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 2 6,844,457 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 3 6,844,332 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 4 6,844,331 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 5 6,844,330 T (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-NOR-vitamin D3 and their uses
- 6 6,806,262 T 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
- 7 6,667,298 T 26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds
- 8 6,627,622 T (20S)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
- 9 6,579,861 T 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
- 10 6,566,352 T 1 .alpha.-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
- 11 6,544,969 T 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds
- 12 6,440,953 T 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
- 13 6,316,642 T 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds

Top**View Cart****Home****Quick****Advanced****Pat Num****Help**

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Bottom](#)[View Cart](#)

Searching 1976 to present...

16/763,023

Results of Search in 1976 to present db for:**((CCL/514/167 AND IN/deluca) AND 19-nor): 41 patents.***Hits 1 through 41 out of 41*[Jump To](#)[Refine Search](#)

ccl/514/167 and in/deluca and 19-nor

PAT. NO. Title

- 1 [6,894,037 T 2-methylene-19-nor-20\(S\)-25-methyl-1 \$\alpha\$ -hydroxycalciferol and its uses](#)
- 2 [6,887,860 T \(20S\)-1 \$\alpha\$ -hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses](#)
- 3 [6,846,811 T \(20S\) 1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses](#)
- 4 [6,844,332 T \(20S\)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses](#)
- 5 [6,844,331 T \(20S\)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses](#)
- 6 [6,844,330 T \(20S\)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-NOR-vitamin D3 and their uses](#)
- 7 [6,806,262 T 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds](#)
- 8 [6,696,431 T 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds](#)
- 9 [6,667,298 T 26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds](#)
- 10 [6,627,622 T \(20S\)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses](#)
- 11 [6,579,861 T 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses](#)
- 12 [6,566,352 T 1.alpha.-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses](#)
- 13 [6,544,969 T 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds](#)
- 14 [6,537,981 T 26,27-Homologated-20-EPI-2-alklidene-19-nor-vitamin D compounds](#)
- 15 [6,440,953 T 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses](#)
- 16 [6,306,844 T Use of 2.alpha.-methyl-19-nor-20\(S\)-1.alpha., 25-dihydroxyvitamin D3 to increase bone strength](#)
- 17 [6,291,444 T Treatment of t-cell immunodeficiencies with vitamin D compounds](#)
- 18 [6,277,837 T 2-alkyl-19-nor-vitamin D compounds](#)

T

- 19 5,945,410 2-alkyl-19-nor-vitamin D compounds
20 5,939,406 T 18-substituted-19-nor-vitamin D compounds
21 5,880,114 T Treatment of immune deficiency with vitamin D compounds
22 5,880,113 T 19-nor-vitamin D compounds
23 5,843,928 T 2-alkylidene-19-nor-vitamin D compounds
24 5,843,927 T 18,19-dinor-vitamin D compounds
25 5,756,489 T 18,19-dinor-vitamin D compounds
26 5,721,225 T 18, 19-Dinor-vitamin D compounds
27 5,716,946 T Multiple sclerosis treatment
28 5,654,292 T Methods and compositions containing vitamin D compounds for improvement of skin conditions
29 5,633,241 T 19-nor-vitamin D compounds
30 5,618,805 T 19-nor-vitamin D compounds
31 5,614,512 T 20-Oxo-pregnacalciferol analogs with binding affinity to the progesterone receptor
32 5,612,326 T Methods containing vitamin D compounds for improvement of skin conditions
33 5,597,815 T Prevention of hyperphosphatemia in kidney disorder patients
34 5,578,587 T Methods and compositions containing vitamin D compounds for improvement of skin conditions
35 5,561,123 T Method of treating proliferative skin disorders with 19-nor-vitamin D compounds
36 5,536,713 T 19-Nor-vitamin D.sub.3 compounds with substituent at 2-position
37 5,459,136 T Methods using vitamin D compounds for improvement of skin conditions
38 5,397,776 T Vitamin D compounds with anti-progesterone activity
39 5,321,018 T Use of 1.alpha.-hydroxylated-19-nor-vitamin D compounds to treat psoriasis
40 5,246,925 T 19-nor-vitamin D compounds for use in treating hyperparathyroidism
41 5,185,150 T Cosmetic compositions containing 19-nor-vitamin D compounds
-

[Top](#)[View Cart](#)[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Next List](#)[Bottom](#)[View Cart](#)

Searching 1976 to present...

16/763, 623

Results of Search in 1976 to present db for:

(CCL/514/167 AND IN/deluca): 105 patents.

Hits 1 through 50 out of 105

[Next 50 Hits](#)[Jump To](#)[Refine Search](#)

ccl/514/167 and in/deluca

PAT. NO. Title

- 1 [6,894,037](#) **T** 2-methylene-19-nor-20(S)-25-methyl-1 α -hydroxycalciferol and its uses
- 2 [6,890,914](#) **T** Method of locking 1 α -OH of vitamin D compounds in axial orientation
- 3 [6,887,860](#) **T** (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
- 4 [6,846,811](#) **T** (20S) 1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 5 [6,844,332](#) **T** (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 6 [6,844,331](#) **T** (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-nor-vitamin D3 and their uses
- 7 [6,844,330](#) **T** (20S)-1.alpha.-hydroxy-2.alpha.-methyl and 2.beta.-methyl-19-NOR-vitamin D3 and their uses
- 8 [6,835,723](#) **T** 2-methylene-19-nor-20(S)-1.alpha.-hydroxy-bis-homo-pregnacalciferol in crystalline form
- 9 [6,806,262](#) **T** 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
- 10 [6,696,431](#) **T** 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
- 11 [6,673,782](#) **T** Treatment of systemic lupus erythematosis
- 12 [6,667,298](#) **T** 26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds
- 13 [6,627,622](#) **T** (20S)-1.alpha.-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
- 14 [6,579,861](#) **T** 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
- 15 [6,566,352](#) **T** 1 .alpha.-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
- 16 [6,544,969](#) **T** 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds
- 17 [6,537,981](#) **T** 26,27-Homologated-20-EPI-2-alklidene-19-nor-vitamin D compounds

- 18 6,482,812 T Method of locking 1.alpha.-OH of vitamin D compounds in axial orientation
19 6,479,474 T Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
20 6,462,031 T Crystalline 1.alpha.-hydroxyvitamin D2 and method of purification thereof
21 6,440,953 T 1.alpha.-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses
22 6,432,936 T Crystalline 1.alpha.-hydroxyvitamin D2 and method of purification thereof
23 6,369,099 T Method of locking 1 .alpha.-OH of vitamin D compounds in axial orientation
24 6,306,844 T Use of 2.alpha.-methyl-19-nor-20(S)-1.alpha., 25-dihydroxyvitamin D3 to increase bone strength
25 6,291,444 T Treatment of t-cell immunodeficiencies with vitamin D compounds
26 6,277,837 T 2-alkyl-19-nor-vitamin D compounds
27 6,114,317 T Method of locking 1.alpha.-OH of vitamin D compounds in axial orientation
28 6,071,897 T Use of vitamin D compounds to prevent transplant rejection
29 6,022,555 T Animal feed containing carboxylic acids
30 5,976,784 T Calcitriol derivatives and their uses
31 5,952,317 T Calcitriol derivatives and their uses
32 5,945,410 T 2-alkyl-19-nor-vitamin D compounds
33 5,942,502 T Method of treating diseases resulting from calcium metabolism disorders
34 5,939,406 T 18-substituted-19-nor-vitamin D compounds
35 5,891,865 T Treatment of arthritic disease induced by infectious agents
36 5,880,114 T Treatment of immune deficiency with vitamin D compounds
37 5,880,113 T 19-nor-vitamin D compounds
38 5,843,928 T 2-alkylidene-19-nor-vitamin D compounds
39 5,843,927 T 18,19-dinor-vitamin D compounds
40 5,767,111 T 18-nor-vitamin D compounds
41 5,756,489 T 18,19-dinor-vitamin D compounds
42 5,721,225 T 18, 19-Dinor-vitamin D compounds
43 5,721,224 T Method of treating metabolic bone diseases with 18-nor-vitamin D compounds
44 5,716,946 T Multiple sclerosis treatment
45 5,661,140 T 18-nor-vitamin D compounds
46 5,654,292 T Methods and compositions containing vitamin D compounds for improvement of skin conditions
47 5,633,241 T 19-nor-vitamin D compounds
48 5,618,805 T 19-nor-vitamin D compounds
49 5,614,512 T 20-Oxo-pregnacalciferol analogs with binding affinity to the progesterone receptor
50 5,612,326 T Methods containing vitamin D compounds for improvement of skin conditions

[Next List](#) | [Top](#) | [View Cart](#)

100

[View Cart](#)

Home

Quick

Advanced

Pat Num

Help

USPTO PATENT FULL-TEXT AND IMAGE DATABASE[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)[Bottom](#)[View Cart](#)*Searching 1976 to present...**10/763,023***Results of Search in 1976 to present db for:****((AN/wisconsin AND 2-ethyl) AND 2-alkyl): 4 patents.***Hits 1 through 4 out of 4*[Jump To](#)[Refine Search](#)

an/wisconsin and 2-ethyl and 2-alkyl

PAT. NO. Title

1 [6,806,262](#) T [2-ethyl and 2-ethylidene-19-nor-vitamin D compounds](#)2 [6,667,298](#) T [26,27-Homologated-20-EPI-2-alkyl-19-NOR-vitamin D compounds](#)3 [6,544,969](#) T [26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds](#)4 [6,316,642](#) T [26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds](#)[Top](#)[View Cart](#)[Home](#)[Quick](#)[Advanced](#)[Pat Num](#)[Help](#)